Zhejiang Garden BiopharmaceuticalLtd Third Quarter 2024 Earnings: EPS: CN¥0.19 (vs CN¥0.059 in 3Q 2023)

Simply Wall St · 10/18 22:38

Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥337.4m (up 40% from 3Q 2023).
  • Net income: CN¥99.4m (up 213% from 3Q 2023).
  • Profit margin: 29% (up from 13% in 3Q 2023).
  • EPS: CN¥0.19 (up from CN¥0.059 in 3Q 2023).
earnings-and-revenue-growth
SZSE:300401 Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zhejiang Garden BiopharmaceuticalLtd Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 8.0% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Zhejiang Garden BiopharmaceuticalLtd that you need to be mindful of.